Sign In
Buy CERT
$8.10
+0.320 (+4.11%)
At Close: Jul 31, 2026
Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024
04:15pm, Wednesday, 09'th Oct 2024
RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third qu
Certara Completes Acquisition of Chemaxon
04:15pm, Wednesday, 02'nd Oct 2024
Certara completes acquiring Chemaxon, a leading cheminformatics company that develops scientific informatics software used by the life sciences industry.
Final Trade: Certara, Nextera Energy, Knight-Swift Transportation and Lululemon
06:37pm, Friday, 27'th Sep 2024
The final trades of the day with the Fast Money traders.
Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug
08:00am, Wednesday, 18'th Sep 2024
Certara shared the results from its collaboration with Ichnos Glenmark Innovation (IGI) on the first-in-human dose prediction and selection for ISB 2001.
Certara to Participate in Upcoming Investor Conferences
04:15pm, Wednesday, 21'st Aug 2024
RADNOR, Pa., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the followi
Certara Launches Phoenix™ Version 8.5 Drug Development Software
04:15pm, Thursday, 15'th Aug 2024
RADNOR, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Phoenix™ version 8.5.
Certara, Inc. (CERT) Q2 2024 Earnings Call Transcript
07:36pm, Tuesday, 06'th Aug 2024
Certara, Inc. (NASDAQ:CERT ) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants David Deuchler - Investor Relations, Gilmartin Group LLC William Feehery - Chief Executive
Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates
07:27pm, Tuesday, 06'th Aug 2024
Certara, Inc. (CERT) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.12 per share a year ago.
Certara Reports Second Quarter 2024 Financial Results
04:15pm, Tuesday, 06'th Aug 2024
RADNOR, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal y
Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio
04:45pm, Tuesday, 09'th Jul 2024
Combined organization brings broader predictive capabilities to drug discovery at scale Reiterates full year 2024 guidance RADNOR, Pa., July 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT),
Certara to Report Second Quarter 2024 Financial Results on August 6th, 2024
04:15pm, Tuesday, 02'nd Jul 2024
RADNOR, Pa., July 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second q
Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software
08:00am, Monday, 17'th Jun 2024
Certara today unveiled its next-generation CoAuthor regulatory writing software. CoAuthor is an advanced writing platform designed for medical writers.
Certara to Participate in the Jefferies Global Healthcare Conference
04:15pm, Wednesday, 29'th May 2024
RADNOR, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Jefferies Global Healthcar
Certara Appoints New Chief Human Resources Officer & General Counsel
08:00am, Tuesday, 21'st May 2024
RADNOR, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has appointed Rona Anhalt as Chief Human Resources Officer and Daniel Co
Swiss National Bank Reduces Stock Holdings in Certara, Inc. (NASDAQ:CERT)
04:43am, Monday, 20'th May 2024
Swiss National Bank cut its position in shares of Certara, Inc. (NASDAQ:CERT – Free Report) by 16.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities a
